

# Ticaglide 60 Tablet

**Brand Name:** Ticaglide 60 Tablet

**Composition:**

Each film-coated tablet contains:

- **Ticagrelor I.P.** – 60 mg
- Excipients – q.s.

**Dosage Form:** Tablet

**Therapeutic Category:** Antiplatelet Agent – P2Y<sub>12</sub> Receptor Antagonist

**Pharmacology & Mechanism of Action:**

Ticagrelor is a reversible oral antagonist of the P2Y<sub>12</sub> receptor on platelets. By inhibiting this receptor, ticagrelor prevents ADP-mediated platelet activation and aggregation, reducing the risk of thrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It acts directly without requiring metabolic activation.

**Indications:**

- Prevention of atherothrombotic events in patients with acute coronary syndrome (ACS)
- Secondary prevention in patients with a history of myocardial infarction or unstable angina
- Adjunct therapy with aspirin for optimal antiplatelet effect

**Dosage & Administration:**

- Recommended dose: 60 mg orally twice daily as directed by the physician
- May be taken with or without food
- Swallow tablet whole; do not crush or chew
- Dose adjustment may be required in patients with hepatic impairment or bleeding risk

**Contraindications:**

- Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage)
- History of intracranial hemorrhage
- Hypersensitivity to ticagrelor or any excipients

**Warnings & Precautions:**

- Increased risk of bleeding; monitor for signs of hemorrhage
- Caution in patients with severe hepatic impairment
- Use with caution in elderly patients or those on concomitant anticoagulants
- Advise patients to report unusual bruising, bleeding, or shortness of breath

**Drug Interactions:**

- CYP3A4 inhibitors (e.g., ketoconazole) may increase ticagrelor plasma levels
- CYP3A4 inducers (e.g., rifampicin) may decrease efficacy
- Avoid strong CYP3A4 inhibitors or inducers

**Adverse Effects:**

- Common: Dyspnea, headache, dizziness, nausea, diarrhea
- Rare: Bleeding, bradyarrhythmia, allergic reactions

**Overdose:**

Symptoms: Severe bleeding, hypotension

Treatment: Supportive care; no specific antidote; platelet transfusion may be considered in severe bleeding

**Storage:**

Store below 25°C in a dry place. Protect from light and moisture. Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,  
Panchkula-134113

TM: Trademark Applied for